Revista Española de Cardiología Revista Española de Cardiología
Rev Esp Cardiol. 2001;54:635-42 - Vol. 54 Núm.05

Temas actuales en biología vascular: puesta al día para el siglo XXI

Cam Patterson a

a Department of Internal Medicine, and Lineberger Comprehensive Cancer Center. University of North Carolina at Chapel Hill. Chapel Hill. North Carolina. EE.UU.

Palabras clave

Biología vascular. Estrés oxidativo. Angiogénesis. Terapia génica. Aterosclerosis.

Resumen

Aunque se da por sentado que los vasos sanguíneos desempeñan un papel primordial en la regulación del sistema cardiovascular en condiciones fisiológicas y patológicas, el mecanismo por el que lo hacen no ha sido comprendido hasta las últimas décadas. El campo de la biología vascular nació de esta apreciación de la primacía de los vasos sanguíneos en la patología cardiovascular. En esta revisión actualizamos varios temas de particular interés en el campo de la biología vascular del siglo xxi: principalmente el papel del estrés oxidativo en la función y la disfunción vascular; la angiogénesis y las terapias génicas angiogénicas, y los biomarcadores emergentes de aterosclerosis. Es probable que cada una de estas áreas experimente avances significativos en los años venideros que tendrán un impacto clínico directo sobre la toma de decisiones y el cuidado de los pacientes con enfermedades cardiovasculares.
El Texto completo solo está disponible en PDF

Bibliografía

1. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977;86: 675-684.
Medline
2. Van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques in characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89: 36-44.
Medline
3. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87: 179-183.
Medline
4. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992;70: 593-599.
Medline
5. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J 1997;11: 118-124.
Medline
6. Investigators GP. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354: 447-455.
Medline
7. Rapola JM, Virtamo J, Ripatti S, Huttunen JK, Albanes D, Taylor PR et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997;349: 1715-1720.
Medline
8. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347: 781-786.
Medline
9. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342: 154-160.
Medline
10. Patterson C, Madamanchi N, Runge MS. The oxidative paradox: another piece of the puzzle. Circ Res 2000;87: 1074-1076.
Medline
11. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74: 1141-1148.
Medline
12. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91: 2546-2551.
Medline
13. Sundaresan M, Yu Z-X, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995;270: 296-299.
Medline
14. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C et al. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: evidence that p47phox may participate in forming this oxidase in vitro and in vivo. J Biol Chem 1999;274: 19814-19822.
Medline
15. Saldeen T, Li D, Mehta JL. Differential effects of *-and *-tocopherol on LDL oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am Coll Cardiol 1999;34: 1208-1215.
Medline
16. Ushio-Fukai M, Zafari A, Fukui T, Ishizaka N, Griendling K. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271: 23317-23321.
Medline
17. Suh YA, Arnold RS, Lassegue B, Shi J, Xu X, Sorescu D et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401: 79-82.
Medline
18. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92: 1866-1874.
Medline
19. Baas AS, Berk BC. Differential activation of mitogen-activated protein kinases by H2O2 and O2­ in vascular smooth muscle cells. Circ Res 1995;77: 29-36.
Medline
20. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272: 20963-20966.
Medline
21. Ruef J, Rao GN, Li F, Bode C, Patterson C, Bhatnagar A et al. Induction of rat aortic smooth muscle cell growth by the lipid peroxidation product 4-hydroxy-2-nonenal Circulation 1998;97: 1071-1078.
22. Ballinger SW, Patterson C, Yan C-N, Doan R, Burow DL, Young CG et al. Hydrogen peroxide­ and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res 2000;86: 960-966.
Medline
23. Pratico D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP et al. IPF2alpha-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998;95: 3449-3454.
Medline
24. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89: 2183-2189.
Medline
25. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994;93: 662-670.
Medline
26. Tsurumi Y, Takeshita S, Chen D, Kearney M, Rossow ST, Passeri J et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94: 3281-3290.
Medline
27. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patientswith critical limb ischemia. Circulation 1998;97: 1114-1121.
Medline
28. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998;98: 2800-2804.
Medline
29. Patterson C, Runge MS. Therapeutic myocardial angiogenesis via vascular endothelial growth factor gene therapy: moving on down the road. Circulation 2000;102: 940-942.
Medline
30. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000;102: 898-901.
Medline
31. Scharwz ER, Speakman MT, Patterson M, Hale SS, Isner JM, Kedes LH et al. Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat ­ angiogenesis and angioma formation. J Am Coll Cardiol 2000;35: 1323-1330.
Medline
32. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100: 468-474.
Medline
33. Hendel RC, Henry TD, Rocha-Singh K, Isner JM, Kereiakes DJ, Giordano FJ et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 2000;101: 118-121.
Medline
34. Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg 1998;39: 783-789.
35. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97: 645-650.
Medline
36. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. Circulation 1999;100: 1865-1871.
Medline
37. Udelson HE, Dilsizian V, Laham RJ, Chronos N, Vansant J, Blais M et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation 2000;102: 1605-1610.
Medline
38. Koestner W. Endarteritis and arteritis. Berl Klin Wochenschr 1876;13: 454-455.
39. Wolinsky H, Glagov S. Nature of species differences in the medial distribution of aortic vasa vasorum in mammals. Circ Res 1967;20: 409-421.
Medline
40. Heistad DD, Armstrong ML. Blood flow through vasa vasorum of coronary arteries in atherosclerotic monkeys. Arteriosclerosis 1986;6: 326-331.
Medline
41. Kumamoto M, Nakashima Y, Sueishi K. Intimal neovascularization in human coronary atherosclerosis: its origin and pathophysiological significance. Human Pathology 1995;26: 450-456.
Medline
42. Barger AC, Beeuwkes R, Lainey LL, Silverman KJ. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. N Engl J Med 1984;310: 175-177.
Medline
43. O'Brien ER, Garvin MR, Dev R, Stewart DK, Hinohara T, Simpson JB et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145: 883-894.
Medline
44. Zamir M, Silver M. Hemorrhagic and microvascular phenomena within the arterial wall. Can J Cardiol 1992;8: 981-984.
Medline
45. Egashira K, Inou Y, Hirooka Y, Yamada A, Marouka Y, Kai H et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91: 29-37.
Medline
46. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 1995;9: 934-938.
Medline
47. O'Brien KD, Allen MD, McDonald TO, Chait A, Harlan JM, Fishbein D et al. Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques. J Clin Invest 1993;92: 945-951.
Medline
48. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996;93: 672-682.
Medline
49. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99: 1726-1732.
Medline
50. Ruef J, Hu ZY, Yin LY, Wu Y, Hanson SR, Kelly AB et al. Induction of vascular endothelial growth factor in balloon-injured baboon arteries. Circ Res 1997;81: 24-33.
Medline
51. McCully KS, Wilson RB. Homocysteine theory of atherosclerosis. Atherosclerosis 1975;22: 215-227.
Medline
52. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77: 1909-1916.
Medline
53. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974;291: 537-543.
Medline
54. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994;91: 6369-6373.
Medline
55. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probably benefits of increasing folic acid intakes. JAMA 1994;274: 1049-1057.
Medline
56. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268: 877-881.
Medline
57. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131: 363-375.
Medline
58. Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med 1911;8: 153-162.
59. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978;148: 335-340.
Medline
60. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000;163: 49-56.
Medline
61. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Circulation 1999;99: 1540-1547.
Medline
62. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of acute myocardial infarction. Circulation 1997;96: 404-407.
Medline
63. Gurfinkel C, Bozovich G, Doroca A, Beck E, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes: The ROXIS pilot study. Lancet 1997;350: 404-407.
Medline
64. Gurfinkel C, Bozovich G, Beck E, Testa E, Livellura B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS study. Eur Heart J 1999;20: 121-127.
Medline
65. Libby P, Galis Z. Cytokines regulate genes involved in atherogenesis. Ann NY Acad Sci 1995;748: 158-168.
Medline
66. Libby P. Changing concepts of atherogenesis. J Int Med 2000;247: 349-358.
67. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentrations of soluble intracellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy young men. Lancet 1998;351: 88-92.
Medline
68. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144: 537-547.
Medline
69. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-979.
Medline
70. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98: 731-733.
Medline

0300-8932/© 2001 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Politica de cookies
x
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.
Política de cookies
x
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí.